ArticleMicrobiology spectrum2023
CRISPR-Cas13a-Based Assay for Accurate Detection of OXA-48 and GES Carbapenemases.
Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 20 citations in OpenAlex.
- The application of the CRISPR-Cas system in Pseudomonas aeruginosa infections.Molecular biology reports · 2026Review
- Advances in CRISPR-Cas for Diagnosis and Treatment ofPathogens (Basel, Switzerland) · 2026Review
- Programmable CRISPR-Cas diagnostic platforms for rapid detection of uropathogens and antimicrobial resistance.Archives of microbiology · 2026Review
- Article
- Interconnected worlds: a comprehensive review of fungal defenses, antimicrobial resistance, and their evolutionary dynamics.IMA fungus · 2026Review
- Thermal optimized PCR coupled to CRISPR-Cas12a for rapid detection of blaOXA-1 resistance gene.PloS one · 2026Article
- Applications and Challenges of CRISPR-Cas Technology for the Detection of Antimicrobial Resistance Genes.Infection and drug resistance · 2026Review
- CRISPR/Cas diagnostics forFrontiers in bioengineering and biotechnology · 2026Review
- The application of the CRISPR-Cas system in Klebsiella pneumoniae infections.Molecular biology reports · 2025Review
- Review
- Detecting antibiotic resistance: classical, molecular, advanced bioengineering, and AI-enhanced approaches.Frontiers in microbiology · 2025Review
- The LAMP-CRISPR-Cas13a technique for detecting the CBASS mechanism of phage resistance in bacteria.Frontiers in microbiology · 2025Article
- Mitigating Antibiotic Resistance: The Utilization of CRISPR Technology in Detection.Biosensors · 2024Review
- Clinical diagnostic value of CRISPR-Cas13a-based molecular technology for tuberculosis.Irish journal of medical science · 2024Article
- Article
- Advancements and applications of loop-mediated isothermal amplification technology: a comprehensive overview.Frontiers in microbiology · 2024Review
- Establishment of a platform based on dual RPA combined with CRISPR/Cas12a for the detection ofFrontiers in bioengineering and biotechnology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem-resistant pathogens have been recognized as a health concern as they are both difficult to treat and detect in clinical microbiology laboratories. Researchers are making great efforts to develop highly specific, sensitive, accurate, and rapid diagnostic techniques, required to prevent the spread of these microorganisms and improve the prognosis of patients. In this context, CRISPR-Cas systems are proposed as promising tools for the development of diagnostic methods due to their high specificity; the Cas13a endonuclease can discriminate single nucleotide changes and displays collateral cleavage activity against single-stranded RNA molecules when activated. This technology is usually combined with isothermal pre-amplification reactions in order to increase its sensitivity. We have developed a new LAMP-CRISPR-Cas13a-based assay for the detection of OXA-48 and GES carbapenemases in clinical samples without the need for nucleic acid purification and concentration. To evaluate the assay, we used 68 OXA-48-like-producing Klebsiella pneumoniae clinical isolates as well as 64 Enterobacter cloacae complex GES-6, 14 Pseudomonas aeruginosa GES-5, 9 Serratia marcescens GES-6, 5 P. aeruginosa GES-6, and 3 P. aeruginosa (GES-15, GES-27, and GES-40) and 1 K. pneumoniae GES-2 isolates. The assay, which takes less than 2 h and costs approximately 10 € per reaction, exhibited 100% specificity and sensitivity (99% confidence interval [CI]) for both OXA-48 and all GES carbapenemases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.